1naresh
Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)
1naresh
Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)


Table 1: 
Demographics, clinical and neurologic characteristics by BGC use
Overall Patients ≥80 Years (n = 808)Non-BGC Use (n = 343, 42.5%)BGC Use (n = 465, 57.5%)P Value
Age (median) (IQR) (yr)85 (83–88)85 (82–88)86 (83–89).001
Female sex (No.) (%)521 (64.5)217 (63.3)304 (65.4).535
NIHSS score at admission (median) (IQR)17 (12–21)18 (13–21)16 (11–21).035
ASPECTS at admission (median) (IQR)9 (7–10)8 (7–10)9 (8–10).008
Time from stroke onset to diagnosis (median) (IQR) (min)280 (180.75–589.25)300 (196.5–564)261 (172–609).069
IV tPA administered (No.) (%)212 (26.2)114 (33.2)98 (21.1)<.001
General anesthesia during EVT (No.) (%)262 (32.4)120 (35)142 (30.5).142
Right-sided occlusion (No.) (%)388 (48)157 (45.8)231 (49.7).272
Level of vessel occlusion (No.) (%).002
 Carotid terminus157 (19.5)79 (23)78 (16.8)
 MCA-M1425 (52.7)189 (55.1)236 (50.9)
 MCA-M2225 (27.9)75 (21.9)150 (32.3)
GPTFR (median) (IQR) (min)7 (5–12)9 (5–16)6 (4–10)<.001
ET time (median) (IQR) (min)25 (12–43)30 (16–49)22 (11–39)<.001
GTR (median) (IQR) (min)35 (22–57)42 (27–66.5)30 (19–49.25)<.001
SR use790 (97.8)335 (97.7)455 (97.8).863
Distal aspiration catheter use (No.) (%)422 (52.2)406 (51.4)16 (88.9).002
Combined technique use (CA + SR)406 (50.2)292 (85.1)114 (24.5)<.001
FPE (mTICI 3) (No.) (%)293 (36.3)112 (32.7)181 (38.9).067
mFPE (mTICI 2c–3) (No.) (%)350 (43.3)137 (39.9)213 (45.8).096
FPE (mTICI 2b–3) (No.) (%)435 (53.8)175 (51)260 (55.9).168
Final No. of passes (No.) (%).991
 1380 (47)161 (46.9)219 (47.1)
 2192 (23.8)81 (23.6)111 (23.9)
 >2236 (29.2)101 (29.4)135 (29)
Technique modification134 (27.9)75 (35.4)59 (21.9).001
mTICI 0 after first pass256 (31.7)118 (34.4)138 (29.7).154
Final mTICI 029 (3.6)17 (5)12 (2.6).073
Final mTICI ≥ 2b (No.) (%)744 (92.1)308 (89.8)436 (93.8).039
Final mTICI ≥ 2c (No.) (%)587 (72.6)227 (66.2)360 (77.4)<.001
Emboli to new territory129 (16)59 (17.2)70 (15.1).410
sICH (No.) (%)53 (6.6)36 (10.5)17 (3.7)<.001
Complications.692
 Perforation11 (29.7)5 (29.4)6 (30)
 Dissection15 (40.5)8 (47.1)7 (35)
NIHSS score at 24 hr (median) (IQR)8 (3–16)10.5 (4–17)7 (2–15).002
Early neurologic deterioration (No.) (%)52 (6.4)26 (7.5)26 (5.6).071
mRS 0-1 at 3 mo191 (23.6)81 (23.6)110 (23.7).989
mRS 0-2 at 3 mo303 (37.5)136 (39.7)167 (35.9).278
Mortality at 3 mo (No.) (%)225 (27.8)107 (31.2)118 (25.4).068
  • Note:—IQR indicates interquartile range; SR, stent retriever; CA, contact aspiration.